DiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming Chronic Kidney Disease Trials
31. Oktober 2017 11:24 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Oct. 31, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “DiaMedica”) (TSX Venture:DMA) (OTCQB:DMCAF) is pleased to announce that Dr. Robert Stanton, Chief of the Kidney and...
DiaMedica Therapeutics Announces the Early Exercise of Warrants from Strategic Investor
27. Oktober 2017 08:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Oct. 27, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX Venture:DMA) (OTCQB:DMCAF), announces the receipt of approximately USD$605,263 in gross proceeds from...
DiaMedica Announces the Initiation of Phase 2 Trial Evaluating DM199 (Recombinant Human KLK1) in Patients with Acute Ischemic Stroke
11. September 2017 08:00 ET
|
DiaMedica Therapeutics Inc.
DM199 may offer substantial benefits to stroke patients with a drug treatment window of 24 hours post-stroke The REMEDY trial is designed to assess the clinical effect of DM199 for acute ischemic...
DiaMedica Issues Stock Option Grant
19. Juni 2017 18:30 ET
|
DiaMedica
MINNEAPOLIS, June 19, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces that the Board of Directors has granted options to...